Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Selcia Limited
Selcia Limited
Activities:
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Selcia joins Eurofins Group
Selcia, specialist provider of custom radiolabelling and integrated drug discovery services, announced it has been acquired by Eurofins Scientific, a global specialist in analytical testing and pharma discovery services
Research & Development
Selcia publishes strategy for structural simplification of natural products
The paper outlines a technique to generate synthetically tractable cyclophilin inhibitors for the treatment of hepatitis C
Ingredients
Selcia opens new dedicated 14C GMP API facility
To help the firm meet increasing demand for 14C radiolabelled compounds
Research & Development
Selcia and Cantab announce drug discovery collaboration
To develop improved antibiotics for multi-drug resistant Gram-negative bacterial infections
Ingredients
Selcia granted patent for drug discovery platform
The patent covers technology underpinning the UK-based company’s CEfrag drug screening service
Research & Development
Selcia exploits in-house IP with demerger
Forms Mitopharm and Selcia Pharma to protect IP while attracting external investment
Research & Development
Convergence Pharmaceuticals and Selcia in r&d collaboration
Aim is to identify and develop high quality candidate molecules for the treatment of chronic pain
Subscribe now